Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction

Elbassioni, Ali Ali Mohamed; Raheem, Anmar A; Song, Jian; Johnston, Alexander S.; Trivett, Cara; Lin, Hong; Zhang, Haobo; Bradley, Ashley; Higgins, Erin; Thomson, Cameron R.; Mooney, Leanne; Koay, Yen Chin; O'Toole, Dylan; Herzyk, Pawel; Nixon, Colin; Blyth, Karen; Hughes, Mark; O'Sullivan, John F.; Lang, Ninian N.; Berry, Colin; Braun, Thomas; Schiattarella, Gabriele G.; Giacca, Mauro; McBride, Martin W.; Nicklin, Stuart A.; Cameron, Ewan R.; Loughrey, Christopher M.; MacDonald, Eilidh A.

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction

Tools

Preview	PDF (Accepted Manuscript) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 2MB
	Other (Supplementary Data) 12MB

Item Type:	Article
Title:	Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction
Creators Name:	Elbassioni, Ali Ali Mohamed, Raheem, Anmar A, Song, Jian, Johnston, Alexander S., Trivett, Cara, Lin, Hong, Zhang, Haobo, Bradley, Ashley, Higgins, Erin, Thomson, Cameron R., Mooney, Leanne, Koay, Yen Chin, O'Toole, Dylan, Herzyk, Pawel, Nixon, Colin, Blyth, Karen, Hughes, Mark, O'Sullivan, John F., Lang, Ninian N., Berry, Colin, Braun, Thomas, Schiattarella, Gabriele G., Giacca, Mauro, McBride, Martin W., Nicklin, Stuart A., Cameron, Ewan R., Loughrey, Christopher M. and MacDonald, Eilidh A.
Abstract:	AIMS: Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence and has limited treatment options. HFpEF is a systemic condition with a broad phenotype including diastolic dysfunction, pulmonary oedema, exercise intolerance, and left ventricular (LV) hypertrophy, collectively resulting in enhanced morbidity and mortality. The transcription factor RUNX1 has recently been identified as a mediator of pathological changes in multiple cardiac diseases, however its role in HFpEF remained unknown. METHODS AND RESULTS: Here we show that inhibition of Runx1 limits adverse cardiac remodelling in a clinically relevant mouse model of HFpEF. Cardiomyocyte-specific tamoxifen-inducible Runx1-deficient mice with HFpEF are protected, with preservation of diastolic function, and attenuation of pulmonary oedema, exercise intolerance, and hypertrophy. Furthermore, targeting Runx1 in HFpEF by using gene transfer or small molecule inhibitor Ro5-3335 improves diastolic function and reduces pulmonary oedema, both in female and male mice. CONCLUSION: Overall, our research enhances our understanding of RUNX1 in cardiac disease and presents a novel translational target for the treatment of HFpEF.
Keywords:	Heart Failure with Preserved Ejection Fraction, Metabolic Heart Failure, Diastolic Dysfunction, Hypertrophy, Pulmonary Oedema, Exercise Intolerance, Animals, Mice
Source:	Cardiovascular Research
ISSN:	0008-6363
Publisher:	Oxford University Press / European Society of Cardiology
Page Range:	cvag106
Date:	26 May 2026
Official Publication:	https://doi.org/10.1093/cvr/cvag106
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year